RESUMO
PURPOSE: To determine the recommended starting doses and pharmacokinetics of irinotecan in cancer patients with impaired liver function treated on a weekly schedule. EXPERIMENTAL DESIGN: Patients with solid tumors who had impaired liver function were enrolled into four groups based on baseline serum total bilirubin and aspartate aminotransferase (AST)/alanine aminotransferase (ALT): Group 1 (n = 19): total bilirubin 1.5 to 3.0 x institutional upper limit of normal (IULN) and ALT/AST Assuntos
Camptotecina/análogos & derivados
, Hepatopatias/patologia
, Neoplasias/metabolismo
, Adulto
, Idoso
, Antineoplásicos Fitogênicos/administração & dosagem
, Antineoplásicos Fitogênicos/sangue
, Antineoplásicos Fitogênicos/farmacocinética
, Antineoplásicos Fitogênicos/toxicidade
, Área Sob a Curva
, Bilirrubina/sangue
, Camptotecina/administração & dosagem
, Camptotecina/sangue
, Camptotecina/farmacocinética
, Camptotecina/toxicidade
, Diarreia/induzido quimicamente
, Feminino
, Humanos
, Infusões Intravenosas
, Irinotecano
, Testes de Função Hepática
, Masculino
, Taxa de Depuração Metabólica
, Pessoa de Meia-Idade
, Neoplasias/sangue
, Neoplasias/patologia
, Neutropenia/induzido quimicamente
, Seleção de Pacientes
RESUMO
PURPOSE: This phase II, multicenter, open-label, single-arm study evaluated the efficacy and safety of irinotecan and gemcitabine as combination chemotherapy for previously untreated patients with unresectable or metastatic pancreatic cancer. PATIENTS AND METHODS: Patients received repeated 21-day cycles at starting doses of gemcitabine 1,000 mg/m(2) over 30 minutes followed immediately by irinotecan 100 mg/m(2) over 90 minutes, both given intravenously on days 1 and 8. Patients were evaluated for objective tumor response, changes in the serum tumor marker CA 19-9, time to tumor progression (TTP), survival, and safety. RESULTS: Forty-five patients were treated. Eleven patients (24%) had 50% or greater reductions in tumor area. These were confirmed one cycle later in nine patients (response rate, 20%; 95% confidence interval, 8% to 32%). Among 44 patients with baseline CA 19-9 determinations, CA 19-9 decreased during therapy in 22 patients (50%) and was reduced by 50% or more in 13 patients (30%). Median TTP was 2.8 months (range, 0.3 to 10.8 months). There were significant (P <.001) correlations between proportional changes in CA 19-9 and radiographic changes in tumor area with regard to extent of change (r =.67), timing of minimum on-study values (r =.85), and tumor progression (r =.89). Median survival was 5.7 months (range, 0.4 to 19.4+ months), and the 1-year survival rate was 27%. Severe toxicities were uncommon and primarily limited to grade 4 neutropenia (2%), grade 4 vomiting (2%), and grade 3 diarrhea (7%). CONCLUSION: Irinotecan/gemcitabine is a new combination that offers encouraging activity in terms of radiographic and CA 19-9 response and notable 1-year survival in pancreatic cancer. The regimen was well tolerated, with minimal grade 3 and 4 toxicities and excellent maintenance of planned dose-intensity.